BioMarin to Attend Three Investor Conferences in 1Q17

Loading...
Loading...

- Leerink Partners 6th Annual Global Healthcare Conference on February 16 in New York City

- Cowen and Company 37th Annual Health Care Conference on March 7 in Boston

- Barclays Global Healthcare Conference on March 15 in Miami

SAN RAFAEL, Calif., Feb. 8, 2017 /PRNewswire/ -- BioMarin Pharmaceutical Inc. BMRN, today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the Leerink Partners 6th Annual Global Healthcare Conference on February 16, 2017 at 1:00pm ET, in New York City. Management will also participate in the Cowen and Company 37th Annual Health Care Conference on March 7, 2017 at 11:20am ET in Boston and the Barclays Global Healthcare Conference on March 15, 2017 at 8:00am ET, in Miami.  To access the live webcasts, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on the site for at least one week following each event.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.  

For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.

Contacts:


Investors  

Media

Traci McCarty 

Debra Charlesworth

BioMarin Pharmaceutical Inc.  

BioMarin Pharmaceutical Inc.

(415) 455-7558  

(415) 455-7451

 

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biomarin-to-attend-three-investor-conferences-in-1q17-300402955.html

SOURCE BioMarin Pharmaceutical Inc.

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...